Extended co-operation agreement to benefit Sartorius customers

12 Jun 2018

Agreement will enable customers to achieve easier scalability of processes ranging from lab-scale to commercial-scale production of biopharmaceuticals.

The Siemens technology group and Sartorius Stedim Biotech (SSB) have signed a long-term co-operation agreement. This agreement provides that SSB will preferably use Siemens automation technologies, including industrial PCs, the S7-1500 software controller, the TIA Portal and the SCADA system Simatic WinCC. These hardware and software components will be used in many products and solutions that SSB offers its customers for the development and manufacture of biopharmaceuticals, such as vaccines and monoclonal antibodies.

Extended co-operation agreement to benefit Sartorius customers

SSB has, for some time, already been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems. To standardize its own product portfolio even further, SSB will introduce a new, configurable automation system for its range of systems. Under the agreement, co-operation between the two companies will, therefore, be extended to further SSB products. These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems, such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT STR series, various filtration systems and the FlexAct system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.

“By introducing this new automation platform and further standardizing our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production,” explained Dr Oscar-Werner Reif, Chief Technology Officer at SSB. “We have found an ideal partner in Siemens as one of the leading companies in automation,” continued Dr Reif.

Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: “We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system lifecycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time-to-market.”

During this year’s ACHEMA trade show that will be taking place from June 11 to June 15, 2018, in Frankfurt, Germany, Siemens and Sartorius Stedim Biotech will be jointly presenting the FlexAct module, a first product based on the new automation platform. Visitors and all others interested are cordially invited to obtain first-hand information at the Siemens AG booth in Hall 11/C3. A presentation on this product will be held in German on June 12 at 1:30 pm. and in English on June 13 at 1:00 p.m. and on 14 June at 2:00 pm.

Read More

Related news

Compact serialization-ready manual workstation

Compact serialization-ready manual workstation

11 Aug 2018

A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
BASF receives award for its portfolio of natural cosmetic ingredients

BASF receives award for its portfolio of natural cosmetic ingredients

7 Aug 2018

Company recognised for its innovation and continual delivery of new natural ingredients.

Read more 
Extended distribution agreement enables customers to continuously improve their bioprocesses

Extended distribution agreement enables customers to continuously improve their bioprocesses

6 Aug 2018

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island

3 Aug 2018

The plant will be first-of-its-kind in the US.

Read more 
Croda invests in SiSaf’s novel bio-courier technology

Croda invests in SiSaf’s novel bio-courier technology

3 Aug 2018

ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.

Read more 
Breast cancer device receives FDA approval

Breast cancer device receives FDA approval

3 Aug 2018

The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.

Read more 
Building contingency plans for an ambiguous post-Brexit market

Building contingency plans for an ambiguous post-Brexit market

31 Jul 2018

One company's positive approach to Brexit preparations, despite the lack of definition.

Read more 
Cherwell publishes guide on environmental monitoring processes and validation

Cherwell publishes guide on environmental monitoring processes and validation

31 Jul 2018

Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.

Read more